Oramed Pharmaceuticals (ORMP) Net Margin (2016 - 2025)

Oramed Pharmaceuticals has reported Net Margin for 8 years, with the latest figure at 382.1% in Q1 2025.

• For the quarter ending Q1 2025, Net Margin changed N/A year-over-year to 382.1%; the trailing twelve-month figure through Dec 2025 stood at 3200.8% (changed N/A YoY), and the FY2025 full-year result was 3200.8%, changed N/A from the prior year.
• Net Margin for Q1 2025 stood at 382.1%, down from 194.81% in the prior quarter.
• The five-year high for Net Margin was 194.81% in Q2 2023, with the low at 1565.32% in Q1 2022.
• Historically, Net Margin has averaged 920.42% across 4 years, with a median of 928.95% in 2022.
• The largest YoY upside for Net Margin was 136795 bps in 2023 against a maximum downside of 105556 bps in 2023.
• Oramed Pharmaceuticals' Net Margin stood at 822.72% in 2021, then slumped by 57 bps to 1290.71% in 2022, then surged by 85 bps to 194.81% in 2023, then slumped by 96 bps to 382.1% in 2025.
• The last three Net Margin figures came in at 382.1% (Q1 2025), 194.81% (Q2 2023), and 509.76% (Q1 2023), per Business Quant data.